Vanda Pharmaceuticals (VNDA) Accounts Payables (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Accounts Payables data on file, last reported at $60.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 33.88% year-over-year to $60.6 million; the trailing twelve-month figure through Mar 2026 stood at $60.6 million (up 33.88% YoY), and the FY2025 full-year result was $68.3 million, up 74.74% from the prior year.
• Accounts Payables retreated to $60.6 million in Q1 2026, from $68.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $68.3 million in Q4 2025 to a low of $31.9 million in Q2 2023.
• A 5-year average of $45.3 million and a median of $45.3 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 96.87% in 2022 and sank 36.44% in 2023, its largest moves.
• Tracing VNDA's Accounts Payables over 5 years: stood at $45.6 million in 2022, then retreated by 15.57% to $38.5 million in 2023, then gained by 1.63% to $39.1 million in 2024, then soared by 74.74% to $68.3 million in 2025, then dropped by 11.24% to $60.6 million in 2026.
• Business Quant data shows VNDA's Accounts Payables at $60.6 million in Q1 2026, $68.3 million in Q4 2025, and $47.6 million in Q3 2025.